Never estimate how often sell-side analysts or
institutional investors can shrug off disappointments from stocks they
want to like, but it looks like Boston Scientific (NYSE: BSX )
is starting to chew up some of the goodwill on the Street. Boston
Scientific isn't performing poorly per se, but the company continues to
report slightly disappointing quarters that run counter to the idea that
it has truly turned a corner in its operating history. Boston
Scientific shares don't look expensive in a world lacking cheap med-tech
names, but it's worth remembering that the Street is already banking on
some pretty aggressive margin improvements and sales growth driven by
devices yet to even secure approval.
Read the full article here:
Are Boston Scientific Corporation's Little Misses Pilling Up?
No comments:
Post a Comment